Mural Oncology Plc Stock Alpha and Beta Analysis
| MURA Stock | 2.04 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Mural Oncology plc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Mural Oncology over a specified time horizon. Remember, high Mural Oncology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Mural Oncology's market risk premium analysis include:
Beta (0.06) | Alpha (0.06) | Risk 0.75 | Sharpe Ratio (0.07) | Expected Return (0.05) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. Mural Oncology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Mural Oncology market risk premium is the additional return an investor will receive from holding Mural Oncology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Mural Oncology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Mural Oncology's performance over market.| α | -0.06 | β | -0.06 |
Mural Oncology Fundamentals Vs Peers
Comparing Mural Oncology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Mural Oncology's direct or indirect competition across all of the common fundamentals between Mural Oncology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Mural Oncology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Mural Oncology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Mural Oncology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Mural Oncology to competition |
| Fundamentals | Mural Oncology | Peer Average |
| Return On Equity | -1.04 | -0.31 |
| Return On Asset | -0.49 | -0.14 |
| Current Valuation | (19.94 M) | 16.62 B |
| Shares Outstanding | 17.34 M | 571.82 M |
| Shares Owned By Insiders | 13.40 % | 10.09 % |
| Shares Owned By Institutions | 46.57 % | 39.21 % |
| Number Of Shares Shorted | 417.44 K | 4.71 M |
Mural Oncology Opportunities
Mural Oncology Return and Market Media
The Stock did not receive any noticable media coverage during the period. Price Growth (%) |
| Timeline |
About Mural Oncology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Mural or other stocks. Alpha measures the amount that position in Mural Oncology plc has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Mural Oncology Upcoming Company Events
As portrayed in its financial statements, the presentation of Mural Oncology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mural Oncology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Mural Oncology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Mural Oncology. Please utilize our Beneish M Score to check the likelihood of Mural Oncology's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Mural Oncology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Mural Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.